Kezitil – 500mg Tablets(Cefuroxime Axetil)
₦5,000.00
Kezitil 500 mg Tablets contain cefuroxime axetil, a broad-spectrum antibiotic belonging to the cephalosporin class. It is effective against a wide range of bacterial infections and is commonly used for both respiratory and urinary tract infections.
Key Features:
- Active Ingredient:
- Cefuroxime Axetil (500 mg): An oral prodrug that converts to cefuroxime, providing effective antibacterial action by disrupting bacterial cell wall synthesis.
- Indications:
- Treatment of various infections, including:
- Respiratory tract infections (e.g., sinusitis, pneumonia)
- Urinary tract infections
- Skin and soft tissue infections
- Bone and joint infections
- Lyme disease (early stage)
- Treatment of various infections, including:
- Dosage Form:
- Available as tablets for convenient oral administration.
Usage:
- Dosage:
- Follow the prescribed dosage from your healthcare provider. Typical adult dosage may range from 250 mg to 500 mg twice daily, depending on the type and severity of the infection.
- Administration:
- Take with food to enhance absorption and reduce gastrointestinal discomfort. Swallow the tablet whole with a glass of water.
Precautions:
- Allergies:
- Inform your healthcare provider of any known allergies to cephalosporins or penicillins.
- Side Effects:
- Common side effects may include gastrointestinal disturbances (nausea, diarrhea), headache, dizziness, and skin rash. Serious side effects should be reported immediately.
- Interactions:
- Discuss any other medications you are taking with your healthcare provider to avoid potential interactions, especially with anticoagulants and other antibiotics.
Storage:
- Store at room temperature, away from moisture and direct sunlight. Keep out of reach of children.
- Very secured payment methods
- Shipping will be calculated on checkout
- Please note that price may increase due to exchange rate, ensure updated price before making payment
Dispensing supervised byPharm. Tope Kareem, B.PharmPCN Reg. 023669
Last updated 28 August 2026How we write and check this informationPCN Premises Licence LAG20247B39C9





Reviews
There are no reviews yet.